AK
AKBA.US Akebia Ther
- Market cap
- USD 132M
- P/E
- -
- P/B
- 6.78x
- ROE
- -211.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is AKBA.US undervalued?
Graham numberThe Graham number of Akebia Ther cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Akebia Ther fundamental analysis
No fundamental analysis for Akebia Ther yet.
Akebia Ther stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Akebia Ther
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in…
Full company profileAkebia Ther financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Akebia Ther annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.54M | 178M | 208M | 335M | 295M | 214M | 292M | 195M | 160M | 236M | 186M |
| Gross Profit | -114M | 177M | 200M | 190M | -601K | 60.2M | 270M | 120M | 97.0M | 197M | 147M |
| Operating Income | -136M | -79.9M | -178M | -286M | -376M | -265M | -80.8M | -46.3M | -50.5M | 23.5M | -30.0M |
| EBITDA | -136M | -76.1M | -176M | -248M | -343M | -227M | 3.06M | -8.27M | -13.7M | 21.7M | -39.3M |
| Net Income | -136M | -76.9M | -172M | -280M | -350M | -245M | -94.2M | -51.9M | -69.4M | -5.35M | -43.1M |
| EPS | -3.60 | -1.77 | -1.47 | -2.36 | -2.53 | -1.48 | -0.52 | -0.28 | -0.33 | -0.02 | -0.16 |
| Balance Sheet | |||||||||||
| Total Assets | 300M | 364M | 997M | 771M | 644M | 529M | 356M | 242M | 221M | 377M | 342M |
| Total Liabilities | 232M | 245M | 361M | 376M | 397M | 455M | 351M | 272M | 270M | 344M | 322M |
| Shareholders' Equity | 68.1M | 119M | 636M | 395M | 248M | 74.0M | 5.23M | -30.6M | -49.2M | 32.6M | 20.4M |
| Cash & Short-term Investments | 260M | 318M | 322M | 148M | 269M | 150M | 90.5M | 42.9M | 51.9M | 185M | 159M |
| Total Debt | 14.0K | - | 15.0M | 108M | 126M | 189M | 99.8M | 104M | 189M | 216M | 60.5M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 57.9M | -56.2M | -97.5M | -257M | -110M | -253M | -73.2M | -23.4M | -40.7M | 68.0M | -20.5M |
| Capital Expenditure | 2.66M | 1.62M | 1.61M | 6.66M | 317K | 59.0K | 114K | 0.00 | 33.0K | 291K | 2.46M |
| Free Cash Flow | 55.2M | -57.8M | -99.1M | -264M | -111M | -253M | -73.3M | -23.4M | -40.7M | 67.7M | -22.8M |
| Ratios | |||||||||||
| ROE | -199.3% | -64.5% | -27.0% | -70.8% | -141.3% | -330.9% | -1,801.6% | - | - | -16.4% | -211.5% |
| ROA | -45.2% | -21.1% | -17.3% | -36.3% | -54.3% | -46.3% | -26.5% | -21.5% | -31.5% | -1.4% | -12.6% |
| Net Profit Margin | -8,843.5% | -43.2% | -82.7% | -83.5% | -118.5% | -114.7% | -32.2% | -26.7% | -43.3% | -2.3% | -23.2% |
| Debt to Equity | 0.00x | - | 0.02x | 0.27x | 0.51x | 2.56x | 19.08x | - | - | 6.63x | 2.97x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Akebia Ther dividends
Akebia Ther has not paid dividends in the last 9 fiscal years.
Who owns Akebia Ther
- Insiders 1.98%
- Institutions 41.74%
- Public & others 56.29%
- Shares outstanding 278M
- Free float 273M
Top funds holding AKBA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 7.91M | 2.85% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 6.64M | 2.39% | 0.00% | Oct 2026 |
| Foord Global Equity (Lux) A | 3.79M | 1.37% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 2.84M | 1.02% | +0.99% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 2.04M | 0.74% | -0.38% | Oct 2026 |
| Fidelity Enhanced Small Cap Core ETF | 2.03M | 0.73% | +0.27% | Oct 2026 |
| Foord Global Equity Class B | 1.83M | 0.66% | 0.00% | Mar 2026 |
| Vanguard Russell 2000 ETF | 1.51M | 0.54% | +1.51% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 1.44M | 0.52% | +0.24% | Oct 2026 |
| Fidelity Extended Market Index | 1.31M | 0.47% | +131.63% | Sep 2026 |
| iShares Micro-Cap ETF | 777K | 0.28% | 0.00% | Oct 2026 |
| Vanguard Health Care ETF | 765K | 0.28% | +0.11% | Sep 2026 |
| Vanguard Strategic Small-Cap Equity Inv | 764K | 0.28% | 0.00% | Sep 2026 |
| Schwab Small Cap Index | 632K | 0.23% | 0.00% | Sep 2026 |
| iShares U.S. Small-Cap Eq Fac ETF | 620K | 0.22% | 0.00% | Oct 2026 |
| Multi-Manager Small Cap Eq Strat Inst | 588K | 0.21% | 0.00% | Sep 2026 |
| AQR Small Cap Multi-Style I | 567K | 0.20% | +523.35% | Jun 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 507K | 0.18% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 507K | 0.18% | -0.05% | Sep 2026 |
| Goldman Sachs ActiveBeta® US SmCp Eq ETF | 457K | 0.16% | 0.00% | Oct 2026 |
Top institutions holding AKBA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 20.0M | 7.20% | +6.92% | Jun 2026 |
| Vanguard Capital Management, LLC | 11.3M | 4.08% | +1.39% | Jun 2026 |
| AQR Capital Management LLC | 9.15M | 3.30% | +410.51% | Jun 2026 |
| Geode Capital Management, LLC | 6.73M | 2.42% | +4.26% | Jun 2026 |
| State Street Corp | 5.39M | 1.94% | -53.58% | Jun 2026 |
| Jacobs Levy Equity Management, Inc. | 4.27M | 1.54% | +894.49% | Jun 2026 |
| Acadian Asset Management LLC | 4.00M | 1.44% | +190.83% | Jun 2026 |
| Nantahala Capital Management, LLC | 4.00M | 1.44% | +100.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 3.69M | 1.33% | +2.40% | Jun 2026 |
| Millennium Management LLC | 3.20M | 1.15% | +34.05% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 2.53M | 0.91% | +14.38% | Jun 2026 |
| Two Sigma Investments LLC | 2.44M | 0.88% | +87.75% | Jun 2026 |
| Charles Schwab Investment Management Inc | 2.30M | 0.83% | +14.13% | Jun 2026 |
| Northern Trust Corp | 2.16M | 0.78% | +11.04% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 1.91M | 0.69% | +7.28% | Jun 2026 |
| FMR Inc | 1.87M | 0.67% | +40.12% | Jun 2026 |
| Qube Research & Technologies | 1.78M | 0.64% | -25.70% | Jun 2026 |
| Citadel Advisors Llc | 1.72M | 0.62% | +23.57% | Jun 2026 |
| UBS Group AG | 1.37M | 0.50% | +78.69% | Jun 2026 |
| Renaissance Technologies Corp | 1.22M | 0.44% | -33.23% | Jun 2026 |
Akebia Ther company profile
- Company name
- Akebia Ther
- Ticker
- AKBA.US
- Exchange
- USA Stocks
- Listed since
- Mar 20, 2014
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 194
- Fiscal year end
- December
- Address
- 180 Third Avenue, Waltham, MA, United States, 02451
- Phone
- 617 871 2098
- Website
- akebia.com
About Akebia Ther
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Akebia Ther management
8- Mr. John P. Butler MBACEO, President & Director · born 1964
- Mr. Erik John Ostrowski M.B.A.Chief Business Officer, Senior VP, CFO & Treasurer · born 1972
- Dr. Steven Keith Burke M.D.Senior VP and Chief Research & Development Officer · born 1961
- Mr. Richard C. MalabreSenior VP & Chief Accounting Officer · born 1961
- Dr. Justin McCue Ph.D.Senior VP & Chief Technology Officer
- Mercedes CarrascoSenior Director of Investor & Corporate Communications
- Ms. Carolyn M. RucciSenior VP, Chief Legal Officer & Secretary · born 1981
- Ms. Meredith BowmanSenior VP & Chief People Officer